Skip to main content
. 2017 Mar 24;55(4):1211–1219. doi: 10.1128/JCM.02219-16

FIG 4.

FIG 4

Quantification of HBV DNA levels in 23 clinical specimens (group 4) infected with HBV bearing amino acid substitutions in the MHR of the S gene (A) and in 18 clinical specimens (group 5) infected with HBV bearing BCP and/or precore mutations (B). HBV DNA levels were measured with the Aptima HBV Quant assay (red squares), the CAP/CTM HBV 2.0 assay (black triangles), or the Abbott RealTime HBV assay (black circles). The red or black dashed lines correspond to the LODs of the Aptima HBV Quant assay (1.0 log IU/ml) and the Abbott RealTime HBV assay (1.0 log IU/ml) or the CAP/CTM HBV 2.0 assay (1.3 log IU/ml), respectively. B-1, blood donor 1; Pt-1, patient 1; gA, genotype A; gB, genotype B; gC, genotype C; gD, genotype D; gE, genotype E; gG, genotype G; nd, not determined due to PCR amplification failure or lack of hybridization to the specific probes in spite of efficient PCR amplification. Amino acid substitutions in the MHR containing the “a” determinant and BCP (AGG or TGA at positions 1762 to 1764) and precore (G or A at position 1896) mutations are indicated.